SPCs are crucial to the IP strategies of life sciences innovators, extending exclusivity when profitability is typically at its highest point. With a number of ECJ decisions addressing tricky disputes in the past 12 months, it is important for biopharma IP professionals to understand recent changes in the obstacles and opportunities involving SPCs